These findings suggest a successful inhibition of KRAS activity downstream of SRC following the dual inhibitor (AXLi + Dasatinib) therapy, contributing to tumor sensitization and the subsequent reduction in tumor volume. This evidence concerns the gene KRAS and neoplasm.